Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gottlieb Takes To Twitter To Raise FDA Morale Amid Shutdown

Executive Summary

Over the past few days US FDA Commissioner Scott Gottlieb has been tweeting about the ongoing government shutdown, including offering his appreciation of agency staffers working under the government shutdown and his support to staffers who have been furloughed. While the agency is operating with carryover user-fee money, the shutdown has limited the agency’s ability to review new products and develop policies.

You may also be interested in...



Scott Gottlieb Calls It Quits After An Active Tenure At US FDA

The commissioner says he will step down next month, leaving a legacy of active policy development, but also a lot of initiatives and pilot projects that are in the middle of being implemented.

2018 US Device Approvals: The Year Of De Novos And Digital Health

It was another record year for novel device approvals by US FDA, driven by the big uptick in de novo classifications for low-to-moderate-risk devices in 2018. Meanwhile, original PMA approvals dropped significantly. An analysis and infographic on FDA device approval trends in 2018.

As US FDA Shutdown Continues, What Will Be The Cost Of Not Spending?

Bolus of applications could be filed once government reopens, but employee morale and recruitment efforts could suffer drop-off.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124445

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel